|

CGT6297 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • Cogent Biosciences, Inc.1

Indications

  • Advanced Solid Tumors, Adult1
  • PIK3CA Mutations1
  • HR Positive/HER-2 Negative Breast Cancer1
  • HER2-low Breast Cancer1
  • Endometrial Cancer1

Scottsdale, Arizona1 trial

A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

HonorHealth Research Institute

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.